Cargando…
MON-069 Uncontrolled Central Precocious Puberty Patient Against GnRH Agonist, After Showing Granuloma Formation and Sterile Abscess to Both Leuprorelin Acetate and Triptorelin Actate
For more than 30 years, Gonadotropin-releasing hormone (GnRH) agonist has been the treatment of choice for central precocious puberty (CPP) to expect regression of secondary sexual characteristics, delayed menarche, and maximization of linear growth. There are several kinds of GnRH agonists such as...
Autores principales: | Kim, Dae Hyun, Choi, Ju-hee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209515/ http://dx.doi.org/10.1210/jendso/bvaa046.183 |
Ejemplares similares
-
Challenges in monitoring GnRH analog treatment in central precocious puberty
por: Latronico, Ana Claudia
Publicado: (2020) -
Gonadotropin-releasing hormone (GnRH) stimulation test before and after GnRH analogue treatment in central precocious puberty; can GnRH test simplify adequately?
por: Yang, You Jean, et al.
Publicado: (2013) -
Treatment of central precocious puberty using low dose GnRH analogs (GnRHa)
por: Jahagirdar, Rahul, et al.
Publicado: (2015) -
GnRH test for the diagnosis of central precocious puberty: is it time to
revisit the protocol ?
por: Sodero, Giorgio, et al.
Publicado: (2023) -
Evaluating the Efficacy of Treatment with a GnRH Analogue in Patients with Central Precocious Puberty
por: Kendirci, H. Nur Peltek, et al.
Publicado: (2015)